Ceresti is leveraging technology and innovative approaches to personalization to enable cost-effective access to a new type of dementia care in the home.


Chronic conditions are expensive. Patients with more than 6 chronic conditions incur 15 times higher expenses than those without chronic conditions.

Chronic conditions compounded by Alzheimer’s Disease and other dementias are even more expensive. This is largely because a person living with dementia is unable to self-manage. In addition to incurring much higher healthcare costs, caring for a person living with dementia is more stressful for caregivers than any other disease.


The elements of effective and appropriate care for a person living with dementia are well understood. Ceresti is the first company to integrate them into a comprehensive series of digital health programs that can be delivered cost-effectively to the home.


Dirk Soenksen is a strategic results-oriented healthcare executive with over 25 years experience. Prior to Ceresti, Mr. Soenksen founded venture-backed Aperio and served in the positions of President/CEO/Chairman until its acquisition by Danaher/Leica Biosystems in 2012. He built a winning team that established Aperio as the recognized global leader in digital pathology, with a staff of 200, a rich portfolio of patents, healthy and growing revenue, multiple FDA clearances, and an installed base of more than 1,000 systems in 35 countries. He earned his AB degree in Chemistry from Bowdoin College, MSEE from the University of Pennsylvania, and his MBA from Pepperdine University.


Kevin Liang, PhD is trained as a neuroscientist and has 15 years experience in clinical study design/management, and regulatory affairs. Before co-founding Ceresti, Dr. Liang was founder and Managing Director of Milestone Research, a boutique medical device consultancy. Prior to Milestone, Dr. Liang was responsible for clinical affairs at Aperio. He earned his doctorate from the University of California, Irvine and is the author of numerous peer-reviewed articles, FDA research protocols and technical publications.


Mark Wrenn has over 30 years experience developing reliable and scalable software architectures. Before co-founding Ceresti, Mr. Wrenn was Sr. Director of Product and Business Development at Aperio where he led the development of a global, HIPAA compliant, cloud-based second opinion network for pathology. He also served as Director of Professional Services where he delivered value-added software and services, including interfaces to third-party IT systems, for a pathology PACS. He earned his BSEng in Computer Science from the University of Connecticut.
Chris Selecky has more than 30 years of experience in managed care and population health management and is Chair of the Board of the Population Health Alliance, the national trade association of the Population Health industry. She is an innovative and accomplished chief executive and entrepreneur in the healthcare industry including co-founding and growing a market leading disease management company from start-up to $130 million in revenues and leading a $2 billion business unit of a publicly traded managed care organization.
She serves on for-profit boards of directors and provides strategic consulting and advice to management teams and investors currently in or seeking to enter the healthcare field. Her areas of expertise include population health management, wellness and prevention, care coordination, disease management, commercial and Medicare managed care, and delivery system management.